J3260 Tobramycin Injection HCPCS Reimbursement

HCPCS Level II code J3260 denotes an injection of tobramycin sulfate, up to 80 mg, used for parenteral administration of this aminoglycoside antibiotic. The code matters nationally because it standardizes billing for a commonly used injectable antibiotic in acute and ambulatory care, supporting consistent reimbursement, inventory management, and clinical documentation across providers and payers. Payment and coverage for injectable antibiotics affect hospital pharmacies, outpatient infusion centers, skilled nursing facilities, and physician practices.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the payer landscape. The publication provides benchmark pricing and reimbursement context where available, summarizes applicable policy considerations and recent coverage developments, and outlines common billing considerations tied to single-dose parenteral antibiotic administration. Data elements not provided in the input are noted as unavailable. This summary is intended for revenue cycle professionals, clinicians involved in parenteral therapy, and policy analysts seeking a national perspective on billing for injectable tobramycin.

Billing Code Overview

HCPCS Level II code J3260 represents an injection of tobramycin sulfate, up to 80 mg. This code describes a single administration of the specified aminoglycoside antibiotic prepared for parenteral delivery.

Service type: Parenteral antibiotic injection
Typical site of service: Ambulatory infusion center, hospital inpatient or outpatient settings, physician office, or other clinical settings where injectable antibiotics are administered

Clinical Context

A typical patient is an adult with a documented gram-negative bacterial infection requiring parenteral aminoglycoside therapy, for example hospitalized patients with complicated urinary tract infection or ventilator-associated pneumonia caused by susceptible organisms. The clinical workflow begins with microbiology confirmation or high clinical suspicion of a tobramycin-susceptible pathogen. A prescriber orders J3260 (Injection, tobramycin sulfate, up to 80 mg) with dose and frequency recorded in the medication administration record. Pharmacy verifies dose, prepares the appropriate concentration for intravenous or inhalation delivery per facility protocol, and labels the syringe or nebulizer vial. Nursing performs an allergy check, verifies patient identity, confirms baseline renal function and auditory status, and administers the dose IV or via inhalation while documenting route, lot number, and time. Therapeutic drug monitoring (serum tobramycin trough/peak) and renal function tests are ordered at recommended intervals to guide dose adjustments. Discharge planning includes outpatient follow-up for labs and instructions on signs of nephrotoxicity or ototoxicity.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/not administered to any patient	Use when part of the single-use vial is wasted and payer requires reporting of discarded drug units

Taxonomy Code	Specialty	Notes
`208000000X`	Internal Medicine	Hospitalists and inpatient physicians ordering parenteral antibiotics
`207Q00000X`	Emergency Medicine	Providers initiating IV tobramycin in ED for severe infections
`207L00000X`	Infectious Disease	Specialists directing aminoglycoside therapy and monitoring
`163W00000X`	Critical Care Medicine	ICU clinicians managing ventilator-associated pneumonia requiring aminoglycosides
`362LP0800X`	Clinical Pharmacist	Pharmacists preparing and dosing aminoglycoside therapy

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J15.9`	Unspecified bacterial pneumonia	Common indication for parenteral aminoglycoside when gram-negative pneumonia is suspected or proven
`J18.9`	Pneumonia, unspecified organism	Empiric therapy for severe pneumonia pending organism identification may include tobramycin in combination regimens
`N39.0`	Urinary tract infection, site not specified	Complicated UTIs with resistant gram-negative organisms may require IV tobramycin
`A41.51`	Sepsis due to Pseudomonas aeruginosa	Tobramycin is active against Pseudomonas and used in severe infections
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	Critical illness requiring broad-spectrum IV antibiotics including aminoglycosides

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, initial, for therapy, prophylaxis, or diagnosis; up to 1 hour	Used when tobramycin is administered as an IV infusion and billing requires an infusion code for facility or professional services
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential IV push of a new substance/drug	Used for additional IV injections of antibiotic administered during the same encounter
`36415`	Collection of venous blood by venipuncture	Used for drawing serum tobramycin levels for therapeutic drug monitoring
`95020`	Inhalation challenge, administration, including pre- and postspirometry	Data not available in the input.
`99232`	Subsequent hospital care, per day, for evaluation and management	Used for ongoing inpatient management of a patient receiving parenteral tobramycin

OpenPayer

Summary & Overview

HCPCS J3260: Injection, Tobramycin Sulfate, Up to 80 mg